BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Van der Speeten K, Stuart OA, Sugarbaker PH. Using pharmacologic data to plan clinical treatments for patients with peritoneal surface malignancy. Curr Drug Discov Technol. 2009;6:72-81. [PMID: 19275544 DOI: 10.2174/157016309787581084] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Dadashzadeh S, Mirahmadi N, Babaei M, Vali A. Peritoneal retention of liposomes: Effects of lipid composition, PEG coating and liposome charge. Journal of Controlled Release 2010;148:177-86. [DOI: 10.1016/j.jconrel.2010.08.026] [Cited by in Crossref: 71] [Cited by in F6Publishing: 70] [Article Influence: 5.9] [Reference Citation Analysis]
2 Padmakumar S, Parayath N, Leslie F, Nair SV, Menon D, Amiji MM. Intraperitoneal chemotherapy for ovarian cancer using sustained-release implantable devices. Expert Opin Drug Deliv 2018;15:481-94. [PMID: 29488406 DOI: 10.1080/17425247.2018.1446938] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
3 Braam HJ, Schellens JH, Boot H, van Sandick JW, Knibbe CA, Boerma D, van Ramshorst B. Selection of chemotherapy for hyperthermic intraperitoneal use in gastric cancer. Crit Rev Oncol Hematol. 2015;95:282-296. [PMID: 25921419 DOI: 10.1016/j.critrevonc.2015.04.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
4 Brücher BL, Piso P, Verwaal V, Esquivel J, Derraco M, Yonemura Y, Gonzalez-Moreno S, Pelz J, Königsrainer A, Ströhlein M. Peritoneal carcinomatosis: cytoreductive surgery and HIPEC--overview and basics. Cancer Invest. 2012;30:209-224. [PMID: 22360361 DOI: 10.3109/07357907.2012.654871] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 5.4] [Reference Citation Analysis]
5 Yonemura Y, Elnemr A, Endou Y, Hirano M, Mizumoto A, Takao N, Ichinose M, Miura M, Li Y. Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer. World J Gastrointest Oncol. 2010;2:85-97. [PMID: 21160926 DOI: 10.4251/wjgo.v2.i2. 85] [Reference Citation Analysis]
6 Cohen MS, Al-kasspooles MF, Williamson SK, Henry D, Broward M, Roby KF. Combination Intraperitoneal Chemotherapy Is Superior to Mitomycin C or Oxaliplatin for Colorectal Carcinomatosis In Vivo. Ann Surg Oncol 2010;17:296-303. [DOI: 10.1245/s10434-009-0669-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
7 Panuganti B, Chang ES, Helm CW, Schwartz T, Hsueh EC, Piao J, Lai J, Veerapong J. Cytoreductive Surgery and Normothermic Intraperitoneal Chemotherapy for Signet Ring Cell Appendiceal Adenocarcinoma With Peritoneal Metastases in the Setting of Cirrhosis. Gastroenterology Res 2018;11:247-51. [PMID: 29915638 DOI: 10.14740/gr1029w] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Yonemura Y, Canbay E, Endou Y, Ishibashi H, Mizumoto A, Miura M, Li Y, Liu Y, Takeshita K, Ichinose M. Peritoneal cancer treatment. Expert Opin Pharmacother. 2014;15:623-636. [PMID: 24617975 DOI: 10.1517/14656566.2014.879571] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
9 Padmakumar S, Menon D. Nanofibrous Polydioxanone Depots for Prolonged Intraperitoneal Paclitaxel Delivery. Curr Drug Deliv 2019;16:654-62. [PMID: 31418659 DOI: 10.2174/1567201816666190816102949] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
10 Ung L, Chua TC, Morris DL. Cure for peritoneal metastases? An evidence-based review. ANZ J Surg 2013;83:821-6. [PMID: 23809063 DOI: 10.1111/ans.12306] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
11 Wang Y, Ren F, Chen P, Liu S, Song Z, Ma X. Effects of CytoReductive surgery plus hyperthermic IntraPEritoneal chemotherapy (HIPEC) versus CytoReductive surgery for ovarian cancer patients: A systematic review and meta-analysis. Eur J Surg Oncol 2019;45:301-9. [PMID: 30786961 DOI: 10.1016/j.ejso.2018.10.528] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
12 Yonemura Y, Elnemr A, Endou Y, Hirano M, Mizumoto A, Takao N, Ichinose M, Miura M, Li Y. Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer. World J Gastrointest Oncol 2010; 2(2): 85-97 [PMID: 21160926 DOI: 10.4251/wjgo.v2.i2.85] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 61] [Article Influence: 6.3] [Reference Citation Analysis]
13 Padmakumar S, Paul-Prasanth B, Pavithran K, Vijaykumar DK, Rajanbabu A, Sivanarayanan TB, Kadakia E, Amiji MM, Nair SV, Menon D. Long-term drug delivery using implantable electrospun woven polymeric nanotextiles. Nanomedicine 2019;15:274-84. [PMID: 30343013 DOI: 10.1016/j.nano.2018.10.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
14 Sugarbaker PH, Bijelic L. Adjuvant bidirectional chemotherapy using an intraperitoneal port. Gastroenterol Res Pract 2012;2012:752643. [PMID: 22888340 DOI: 10.1155/2012/752643] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
15 Yonemura Y, Endou Y, Sasaki T, Hirano M, Mizumoto A, Matsuda T, Takao N, Ichinose M, Miura M, Li Y. Surgical treatment for peritoneal carcinomatosis from gastric cancer. Eur J Surg Oncol. 2010;36:1131-1138. [PMID: 20933363 DOI: 10.1016/j.ejso.2010.09.006] [Cited by in Crossref: 71] [Cited by in F6Publishing: 66] [Article Influence: 5.9] [Reference Citation Analysis]
16 Zhang J, Tang D, Chen J, Wang S, Gao J, Ye N, Wang D. Lethal effect of a hyperthermic CO2 pneumoperitoneum on gastric cancer cells. Clinics and Research in Hepatology and Gastroenterology 2014;38:520-7. [DOI: 10.1016/j.clinre.2013.12.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
17 Brenkman HJF, Päeva M, van Hillegersberg R, Ruurda JP, Haj Mohammad N. Prophylactic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer-A Systematic Review. J Clin Med 2019;8:E1685. [PMID: 31618869 DOI: 10.3390/jcm8101685] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
18 Hakeam HA, Arab A, Azzam A, Alyahya Z, Eldali AM, Amin T. Incidence of leukopenia and thrombocytopenia with cisplatin plus mitomycin-c versus melphalan in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Cancer Chemother Pharmacol. 2018;81:697-704. [PMID: 29429054 DOI: 10.1007/s00280-018-3537-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
19 Sardi A, Jimenez W, Nieroda C, Sittig M, Shankar S, Gushchin V. Melphalan: A Promising Agent in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol 2014;21:908-14. [DOI: 10.1245/s10434-013-3407-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
20 Kusamura S, Azmi N, Fumagalli L, Baratti D, Guaglio M, Cavalleri A, Garrone G, Battaglia L, Barretta F, Deraco M. Phase II randomized study on tissue distribution and pharmacokinetics of cisplatin according to different levels of intra-abdominal pressure (IAP) during HIPEC (NCT02949791). Eur J Surg Oncol 2021;47:82-8. [PMID: 31262599 DOI: 10.1016/j.ejso.2019.06.022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
21 Yonemura Y, Canbay E, Endou Y, Ishibashi H, Mizumoto A, Li Y, Liu Y, Takeshita K, Ichinose M, Takao N, Saitou T, Noguchi K, Hirano M, Glehen O, Brűcher B, Sugarbaker PH. Comprehensive treatment for the peritoneal metastasis from gastric cancer. World J Surg Proced 2015; 5(2): 187-197 [DOI: 10.5412/wjsp.v5.i2.187] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
22 Ni X, Wu P, Wu J, Ji M, Tian B, Jiang Z, Sun Y, Xing X, Jiang J, Wu C. Hyperthermic intraperitoneal perfusion chemotherapy and response evaluation in patients with gastric cancer and malignant ascites. Oncol Lett. 2017;14:1691-1696. [PMID: 28789396 DOI: 10.3892/ol.2017.6342] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
23 Yonemura Y, Elnemr A, Endou Y, Hirano M, Mizumoto A, Takao N, Ichinose M, Miura M, Li Y. Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer. World J Gastrointest Oncol. 2010;2:85-97. [PMID: 21160926 DOI: 10.4251/wjgo.v2.i2. 85] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Rampone B, Schiavone B, Martino A, Confuorto G. Current role of hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis from colorectal cancer. World J Gastroenterol 2010; 16(11): 1299-1302 [PMID: 20238394 DOI: 10.3748/wjg.v16.i11.1299] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
25 Ge J, Liu T, Lei T, Li X, Song K, Azizi S, Liu H, Tang M. Retrospective Cohort Study of Intraoperative Administration of Sustained-Release 5-Fluorouracil Implants in Advanced Gastric Cancer Patients. Front Pharmacol 2021;12:659258. [PMID: 33927633 DOI: 10.3389/fphar.2021.659258] [Reference Citation Analysis]
26 Ceresoli M, Verrengia A, Montori G, Busci L, Coccolini F, Ansaloni L, Frigerio L. Effect of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on relapse pattern in primary epithelial ovarian cancer: a propensity score based case-control study. J Gynecol Oncol 2018;29:e53. [PMID: 29533028 DOI: 10.3802/jgo.2018.29.e53] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
27 Sakata S, Tan TG, Kostadinov D, Ahmadi N, Dayal SP, Tzivanakis A, Mohamed F, Carr NJ, Cecil TD, Moran BJ. Patients undergoing cytoreductive surgery for peritoneal malignancy of appendiceal origin should be consented for umbilical excision as 30% have umbilical infiltration. Colorectal Dis 2021;23:1153-7. [PMID: 33544973 DOI: 10.1111/codi.15571] [Reference Citation Analysis]